格列美脲治疗2型糖尿病伴肥胖患者的临床效果及药理分析

目的 探讨2型糖尿病伴肥胖患者施以格列美脲治疗的临床效果,并作药理分析。方法 46例2型糖尿病伴肥胖患者,根据随机数字表法分为观察组和对照组,每组23例。对照组患者给予格列吡嗪缓释片治疗,观察组患者给予格列美脲片治疗。比较两组患者治疗前后血糖指标[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1c)]、血脂[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)]及体质量指数(BMI)。结果 治疗后,观察组患者FPG、2 h PG、FINS、HbA1c水平分别为(6.04±0.43)mmol/L、(11.12±2.52)mmol/L、(657.84±10.37)pmol/L、(6.46±0.58)%,均低于对照组的(7.45±0.27)mmol/L、(14.24±2.09)mmol/L、(704.29±11.09)pmol/L、(8.53±0.79)%,差异均具有统计学意义(P<0.05)。观察组患者TC、TG、LDL-C、BMI水平分别为(3.24±0.79)mmol/L、(1.88±0.69)mmol/L、(1.96±0.48)mmol/L、(23.05±2.55)kg/m2,均低于对照组的(4.75±0.38)mmol/L、(2.35±0.75)mmol/L、(2.95±0.66)mmol/L、(27.76±4.10)kg/m2,差异均具有统计学意义(P<0.05)。结论 以格列美脲治疗2型糖尿病伴肥胖患者,可使患者血糖及血脂水平得以有效控制,同时可减轻其肥胖程度,具较高应用价值。

Clinical effect of glimepiride in patients with type 2 diabetes mellitus and obesity and its pharmacological analysis

Objective To discuss the clinical effect of glimepiride in patients with type 2 diabetes mellitus and obesity and its pharmacological analysis.Methods A total of 46 patients with type 2 diabetes mellitus and obesity were divided into observation group and control group by random number table method,with 23 cases in each group.The control group was treated by oral administration of glipizide sustained release tablets,and the observation group was treated by glimepiride tablets.The blood glucose[fasting plasma glucose(FPG),2 h postprandial glucose(2 h PG),fasting insulin(FINS),glycated hemoglobin(HbA1c)]before and after treatment,blood lipid[total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C)]and body mass index(BMI)were compared between the two groups.Results After treatment,the levels of FPG,2 h PG,FINS and HbA1c of the observation group were(6.04±0.43)mmol/L,(11.12±2.52)mmol/L,(657.84±10.37)pmol/L and(6.46±0.58)%respectively,which were lower than those of the control group(7.45±0.27)mmol/L,(14.24±2.09)mmol/L,(704.29±11.09)pmol/L and(8.53±0.79)%,and the difference was statistically significant(P<0.05).The levels of TC,TG,LDL-C and BMI of the observation group were(3.24±0.79)mmol/L,(1.88±0.69)mmol/L,(1.96±0.48)mmol/L and(23.05±2.55)kg/m2 respectively,which were lower than those of the control gorup(4.75±0.38)mmol/L,(2.35±0.75)mmol/L,(2.95±0.66)mmol/L and(27.76±4.10)kg/m2,and the difference was statistically significant(P<0.05).Conclusion Glimepiride can effectively control the blood glucose and lipid level of patients with type 2 diabetes mellitus and obesity,and reduce the degree of obesity.It contains high application value.